Indaptus Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 3.09 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 474.57M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Details
| Name | Indaptus Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 5 |
| Founded | 2000 |
| Ceo | Junyi Dai |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US45339J2042 |
| Cusip | 45339J204 |
| Cik | 1857044 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Junyi Dai | Chief Executive Officer and Chairman |
| Yu Ding | Chief Financial Officer |
Contact
| Address | Three Columbus Circle, 15th Floor, New York, New York 10019, United States |
| Phone | 646 427 2727 |
| Website | https://indaptusrx.com |